106 reports of this reaction
1.3% of all DEXTROAMPHETAMINE SULFATE reports
#17 most reported adverse reaction
DISTURBANCE IN ATTENTION is the #17 most commonly reported adverse reaction for DEXTROAMPHETAMINE SULFATE, manufactured by Amneal Pharmaceuticals LLC. There are 106 FDA adverse event reports linking DEXTROAMPHETAMINE SULFATE to DISTURBANCE IN ATTENTION. This represents approximately 1.3% of all 8,480 adverse event reports for this drug.
Patients taking DEXTROAMPHETAMINE SULFATE who experience disturbance in attention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISTURBANCE IN ATTENTION is a less commonly reported adverse event for DEXTROAMPHETAMINE SULFATE, but still significant enough to appear in the safety profile.
In addition to disturbance in attention, the following adverse reactions have been reported for DEXTROAMPHETAMINE SULFATE:
The following drugs have also been linked to disturbance in attention in FDA adverse event reports:
DISTURBANCE IN ATTENTION has been reported as an adverse event in 106 FDA reports for DEXTROAMPHETAMINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISTURBANCE IN ATTENTION accounts for approximately 1.3% of all adverse event reports for DEXTROAMPHETAMINE SULFATE, making it a notable side effect.
If you experience disturbance in attention while taking DEXTROAMPHETAMINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.